研究和分析恩替卡韦联合复方鳖甲软肝片治疗乙肝肝硬化的临床疗效

The Research and Analysis of Clinical Efficacy of Entecavir Combined with Fufangbiejiaruanganpian Treatment of Hepatitis B Cirrhosis

目的研究和分析恩替卡韦联合复方鳖甲软肝片治疗乙肝肝硬化的临床疗效。方法选取我院2014年4月-2016年4月收治的60例乙肝肝硬化患者作为研究对象,使用随机数表法将60例患者随机分为对照组和观察组各30例,对照组患者仅采用恩替卡韦治疗,观察组患者采用恩替卡韦联合复方鳖甲软肝片治疗,治疗结束后,对比两组患者治疗总有效率。结果治疗结束后,观察组患者的治疗总有效率明显优于对照组,观察组患者中出现不良反应的有1例(3.33%),对照组患者中出现不良反应的有3例(10.00%),观察组患者出现不良反应的几率也明显低于对照组,两组数据差异显著(P<0.05),有统计学意义。结论使用恩替卡韦联合复方鳖甲软肝片治疗乙肝肝硬化治疗效果显著,值得临床推广应用。

Objective To study the clinical curative effect and analysis of entecavir combined with Fufangbiejiaruanganpian treatment of hepatitis B cirrhosis.60 cases of patients with hepatitis B cirrhosis.Methods Selected 60 patients with hepatitis B cirrhosis treated in our hospital from April 2014 to April 2016,60 patients were randomly divided into control group and observation group with 30 cases in each group,the patients in control group only received entecavir Cave treatment,observation group were treated by entecavir combined with Fufangbiejiaruangan Cave treatment,treatment after the end of treatment were compared between two groups total efficiency.Results After the treatment,observe the total effective rate of treatment group was significantly better than the control group,the observation group of patients with adverse reactions in 1 cases(3.33 %),the control group of patients with adverse reactions in 3 cases(10 %),the observation probability of patients with adverse reactions was significantly lower than the control group,the difference the data of the two groups was significant(P<0.05),there was statistical significance.Conclusion The use of entecavir combined with Fufangbiejiaruangan treatment of hepatitis B cirrhosis treatment effect is significant,worthy of clinical application.